EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retatrutida como estratégia terapêutica emergente no tratamento da obesidade e do diabetes mellitus tipo 2

Gabriel Reis de Oliveira, Samara Rios Sancho Gonçalves, Lucas Reis de Oliveira, Mary Miranda Cairo Guimarães, Larissa Borges Nobre, Luciano de Oliveira Souza Tourinho

Revista ft · 31.05.2026 · 30 (158) · 01-19

DOI: 10.69849/v83xr454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista ft, online erschienen am 31.05.2026. Verfasst von Gabriel Reis de Oliveira und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Considered twin epidemics of high prevalence, obesity and Type 2 Diabetes Mellitus (T2DM) stand out as relevant contributors to morbidity and mortality related to Noncommunicable Chronic Diseases (NCDs), representing major challenges for public health. The close relationship between these two conditions makes them interdependent, since the pathophysiological mechanisms of obesity predispose individuals to the development of T2DM, making obesity its main risk factor. Given the complexity of these diseases, which involve both modifiable and non-modifiable factors, pharmacological interventions that go beyond glycemic control and also promote body weight reduction are increasingly necessary, aiming to improve cardiometabolic parameters. Retatrutide is a triple agonist of the GIP, GLP-1, and glucagon receptors, proposed to act simultaneously on satiety, glucose-dependent insulin secretion, adipose metabolism, and energy mobilization. This article aims to critically analyze the efficacy, safety, and clinical applicability of retatrutide in adults with obesity and/or T2DM. This is an integrative/narrative review, structured according to the PICO/T strategy, with an exploratory synthesis of effect measures extracted from clinical trials, systematic reviews, and meta-analyses published between 2021 and 2026. The central themes selected were: pathophysiological rationale, mechanism of action, weight-loss and glycemic efficacy, safety, incretin-based comparators, methodological gaps, and applicability to the Brazilian context. Direct evidence indicates substantial weight loss and HbA1c reduction, especially with higher doses, although these findings still derive predominantly from phase 1b/2 studies. It is concluded that retatrutide is a promising investigational therapy, although its clinical position will depend on phase 3 trials, long-term safety data, cost-effectiveness analyses, and equitable access.

Zitieren

APA

Oliveira, G. R. D., Gonçalves, S. R. S., Oliveira, L. R. D., Guimarães, M. M. C., Nobre, L. B., & Tourinho, L. D. O. S. (2026). Retatrutida como estratégia terapêutica emergente no tratamento da obesidade e do diabetes mellitus tipo 2. Revista ft, 30(158), 01-19. https://doi.org/10.69849/v83xr454

Vancouver

Oliveira GRD, Gonçalves SRS, Oliveira LRD, Guimarães MMC, Nobre LB, Tourinho LDOS. Retatrutida como estratégia terapêutica emergente no tratamento da obesidade e do diabetes mellitus tipo 2. Revista ft. 2026;30(158):01-19. doi:10.69849/v83xr454

BibTeX
@article{Oliveira2026,
  author = {Oliveira, Gabriel Reis de and Gonçalves, Samara Rios Sancho and Oliveira, Lucas Reis de and Guimarães, Mary Miranda Cairo and Nobre, Larissa Borges and Tourinho, Luciano de Oliveira Souza},
  title = {Retatrutida como estratégia terapêutica emergente no tratamento da obesidade e do diabetes mellitus tipo 2},
  journal = {Revista ft},
  year = {2026},
  volume = {30},
  number = {158},
  pages = {01--19},
  doi = {10.69849/v83xr454}
}
Kostenlos starten →